Last November, the U.S. FDA announced that it had completed an evaluation of UPSIDE Foods’ cultured animal cell foods and had “no further questions at this time about the firm’s safety conclusion.” While the FDA pointed out that there were still other regulatory hurdles to overcome for cell-cultured foods could be brought to market, namely from the USDA and FSIS, the announcement was seen by many as an important step in adding another option to the alternative protein space—one of a number of trends involving alternative protein in the past year.
The new system is designed to eliminate barriers faced by current cultivated meat approaches that rely on enormous bioreactors infeasible for scalable animal cell cultivation.
The company says the achievement lays the groundwork for new species expansion and accelerates momentum as the company prepares commercialization in the U.S.
The $10.8 million in funding, led by S2G Ventures, will support the construction of a pilot plant in Singapore and the marketing of products globally
July 1, 2022
Avant, a biotechnology company and developer of an end-to-end platform for cell-cultivated fish and seafood, announced its over $10.8 million round led by S2G Ventures, the direct investment team of Builders Vision, an impact platform dedicated to building a humane and healthy planet.
Deep-tech food company expects collaboration to produce hybrid alternative meat products that are nutritious and delicious
May 20, 2022
MeaTech 3D Ltd. has announced that its wholly owned Belgian subsidiary, Peace of Meat, has signed a joint development agreement with ENOUGH, a player in the field of mycoprotein—a fungi-based fermented food ingredient.